URGN Overview

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is40.25 USD with a low forecast of 31.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Urogen Pharma Ltd revenue for the last quarter amounts to 37.84M USD, increased 54.03

Urogen Pharma Ltd. EPS for the last quarter amounts to -0.54 USD, decreased -16.92

Urogen Pharma Ltd (URGN) has 291 emplpoyees as of March 26 2026.

Today URGN has the market capitalization of 882.12M USD.